{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-220578","form_type":"8-K","ticker":"UPB","cik":"0002022626","company_name":"Upstream Bio, Inc.","filed_at":"2026-05-13T11:05:16+00:00","discovered_at":"2026-05-13T11:10:00.319675+00:00","generated_at":"2026-05-13T11:14:19.391813+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Upstream Bio reports Q1 net loss $40.6M; Phase 3 plans on track for 2027","bullets":["Cash, cash equivalents and short-term investments $294.6M as of March 31, 2026; expected to fund operations through 2027.","Net loss $40.6M vs $27.3M YoY; R&D expenses $36.6M (up from $25.8M) driven by clinical and manufacturing costs.","End-of-Phase 2 meetings with FDA planned mid-2026; Phase 3 initiations in severe asthma and CRSwNP expected Q1 2027.","Phase 2 VENTURE COPD trial capping enrollment at >400 participants; data now expected H2 2027.","Phase 2 VALOUR LTE study in severe asthma completed enrollment with >90% retention of eligible patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-220578","json":"https://secwatch.observer/filing/0001193125-26-220578.json","markdown":"https://secwatch.observer/filing/0001193125-26-220578.md","text":"https://secwatch.observer/filing/0001193125-26-220578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022626/000119312526220578/0001193125-26-220578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022626/000119312526220578/upb-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T11:14:19.391813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}